New Publication Describes Mechanism of Action for Tβ4 in Corneal Wound Healing and Regeneration
R
egeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (RegeneRx or the Company), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced the publication of a new scientific study demonstrating a mechanism of action of thymosin beta 4 (Tβ4) on human corneal epithelial cell migration and the downstream signaling pathways.
Although Tβ4 is in phase 3 clinical trials for treatment of eye disorders such as dry eye syndrome and neurotrophic keratitis, the effect of Tβ4 on human corneal epithelial cell (HCEC) migration and proliferation and the precise downstream signaling pathway(s) have not been completely identified.
The results of this study suggest that Tβ4-mediated HCEC proliferation and migration are associated with increased ATP levels, P2X7 R-mediated Ca2+ influx, and the ERK1/2 signaling pathway, which describes one of the mechanisms of action for Tβ4-mediated corneal healing and regeneration.
The study was conducted by H.M. Yang et al., who are either employees or consultants of GtreeBNT, a joint venture partner with RegeneRx Biopharmaceuticals, Inc. for the development of RGN-259 in the U.S. The study was funded by GtreeBNT and published in the journal, Current Eye Research, on line, 02 Apr 2020, https//doi.org/10.1080/02713683.2020.1748891
✔️ New Publication Describes Mechanism of Action for Tβ4 in Corneal Wound Healing and Regeneration
💕 Found this article helpful? Spread the word and support us!